Marrone Bio Innovations Submits Novel Bioherbicide to the EPA for Regulatory Approval

Novel mode of action for resistant weeds such as palmer amaranth

Marrone Bio Innovations (NASDAQ:MBII)

We are excited about what we have seen so far in 014 development. We have more work to determine appropriate doses on key target weeds, water volume, adjuvans and further expansion of the spectrum.”

— Amit Vasavada, Senior Vice President of R&D and Chief Technology Officer

DAVIS, CA, USA, August 14, 2018 /EINPresswire.com/ — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, has submitted the registration package for its new bioherbicide, MBI-014, to the United States Environmental Protection Agency (EPA).

Weeds are a major source of yield losses for most cropping systems. According to various market research reports, herbicides account for 40% of the $50 billion global pesticide market. Of the approximately $7.2 billion chemical pesticides sold in the U.S. each year, nearly $4 billion are chemical herbicides.

Grower surveys repeatedly show that weed control is the number one cost of organic food production since chemical herbicides are not allowed. In organic growing systems, herbicide options are extremely limited, consisting almost entirely of non-selective soaps and acids that typically require repeat applications, lack residual activity, only affect plant areas into which they come in direct contact, and sometimes cost more than hand weeding. According to the Organic Trade Association, organic food sales reached $45 billion in the U.S. and is the fastest growing segment of food, growing an average of 9.1% annually since 2008.

MBI-014 is a water dispersible microbial herbicide made from a new species of heat-killed bacteria, Burkholderia rinojensis (strain A396). This new herbicide has a novel mode of action per research conducted at the USDA Agricultural Research Service. While additional development work and field trials need to be conducted, MBI-014 could prove to be a valuable new tool for weed control when used in conjunction with other herbicides in a grower’s integrated pest management (IPM) program.

MBI-014 demonstrates post-emergent herbicidal activity across a range of weeds in laboratory and field tests. It shows evidence of uptake and moderate movement through different plant tissues. MBI-014 is most effective on some of the most serious weeds, some of which have developed resistance to multiple herbicide classes, such as palmer amaranth, waterhemp and others in the pigweed family (Amaranthacae).

“We are excited about what we have seen so far in the development of MBI-014,” said Amit Vasavada, Senior Vice President of R&D and Chief Technology Officer at Marrone Bio Innovations. “We do have more work to do in order to determine such things as appropriate doses on key target weeds, water volume required, adjuvant package needed and further expansion of the spectrum of targeted weeds.”

Sources of cited information: Phillips McDougall Agribusiness Intelligence, Weed Science Society of America, University of Missouri, Organic Trade Association, Organic Farming Research Foundation, USDA.

Pam Marrone
Marrone Bio Innovations
5307502800
email us here


Source: EIN Presswire

SMi’s Exclusive Interview with Abon Pharmaceuticals, Director just released

Dr. Yanming Zu, Director at Abon Pharmaceuticals

Interview with Dr. Yanming Zu, Director

An exclusive interview with Dr. Yanming Zu, Director at Abon Pharmaceuticals has been released

NEW JERSEY , ISELIN, USA, August 14, 2018 /EINPresswire.com/ — SMi Reports: An exclusive interview with Dr. Yanming Zu, Director at Abon Pharmaceuticals, who will be presenting an Opening Address on 'Challenges of lyophilized product development’, in the run-up to the 4th annual Lyophilization USA Conference taking place 15th-16th November 2018, Iselin, New Jersey, USA. The two-day conference promises to provide a stimulating environment for delegates, with an impressive list of international industry experts from Pfizer, Amgen and Merck sharing their experience and thought-leadership across a full conference programme.

SMi Group caught up with Dr. Yanming Zu to talk about her role in the field and her responsibility for the generic and proprietary product development, as a registered pharmacist and her career as a Senior Principle Scientists joining Abon Pharmaceuticals back in 2009. Dr. Zu’s research and development work contributed to a number of ANDA filings and approvals, and generated several patents, research papers, review articles and presentations.

–SNAPSHOT OF INTERVIEW–

Q . What is the greatest challenge to overcome in the field at the moment?
A. Poor solubility and instability of new chemical entities are challenges in the field of lyophilisation, especially with the increasing number of the insoluble and unstable drugs."

Q. What technology has really caught your eye in the Lyophilization field in the past year?
A. Controlled nucleation is one of the most typical trends in the industry, as uncontrolled nucleation introduces significant heterogeneity affecting the product quality, while the controlled nucleation technology allows for improved uniformity, consistence and thus the product quality assurance."

– Download the full interview online – http://www.lyophilization-usa.com/PR07

At SMi’s 4th Annual Lyophilization USA 2018 Conference you will gain insight into:
• Continuous freeze-drying technologies
• Developments in bulk lyophilization technology
• How to overcome challenges in lyophilization of high concentrated solutions and high-density biologic materials
• Process optimization of lyophilization from a regulatory perspective
• Strategies to validate the lyophilization process
• Methods beyond lyophilization: Spray drying, foam drying and microwave drying
• Use of artificial intelligence in lyophilisation

The conference’s last early bird saving of $100 expires on September 28th and delegates are urged to book soon to join an unrivalled gathering of international expert speakers and industry professionals for 5+ hours of pure networking. Visit the website to download the full speaker interviews, see the agenda and keep up to date with the latest developments at http://www.lyophilization-usa.com/PR07

Follow us on: Twitter – @SMIpharm & #lyousa | LinkedIn – SMi Pharma

—- ENDS —-

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+44 (0) 207 827 6088
email us here


Source: EIN Presswire

Mary Beth McGuinn LCSW to be Featured on CUTV News Radio

RAMSEY, NEW JERSEY, UNITED STATES, August 14, 2018 /EINPresswire.com/ — Mary Beth McGuinn, LCSW is a seasoned therapist and a go-to person when working with clients going through transitions in their lives. Worry, depression and anxiety are often a consequence of not feeling confident when changes arise. Feeling disconnected from life, people often feel powerless to make the right decisions. McGuinn, LCSW uses her expertise from 20 years in a therapeutic practice to guide clients to be able to manage their lives, have less anxiety and be more confident. Mastering techniques to take things down a notch, clients leave sessions with less tension and more hope for resolving what is on their minds.

“My focus in therapy and coaching with clients is to help them be the best they can be and shift from being a victim to being a victor,” says McGuinn.

“It is not about looking at someone and saying what is wrong with this person,” says McGuinn. “I look at clients I work with and wonder, ‘What has kept them stuck in life? I explore this with my clients in therapy and help them get clear on where they are going. I am a life-long learner, always learning new information to bring to my clients from Neuroscience to Energy Psychology.”

Pairing Energy Psychology, EFT Tapping with traditional therapy and coaching, McGuinn’s integrative approach allows clients to not only clear negative thoughts but help ease tensions in your body. Her eclectic approach draws from Psychoanalysis, Cognitive Behavioral Therapy and Grief Recovery Work.

In addition to receiving Advance Standing at Adelphi University, she has done post graduate work at the New Jersey Institute for Training in Psychoanalysis and a certification from the Grief Recovery Institute. She co-authored with Jack Canfield a recent bestselling book titled the Road to Success Volume 1.

She works in Ramsey, New Jersey and can be found on the therapist directory of PsychologyToday.com.

CUTV News Radio will feature Mary Beth McGuinn in an interview with Jim Masters on July 25th at 11am EDT.

Listen to the show on BlogTalkRadio.

If you have a question for our guest, call (347) 996-3389

Lou Ceparano
CUTV News
(631) 850-3314
email us here


Source: EIN Presswire

HealthTech Healx raise $10m to accelerate drug discovery, prior to speaking at Orphan Drugs and Rare Diseases Conference

Orphan Drugs and Rare Diseases 2018

Orphan Drugs and Rare Diseases 2018

HealthTech Healx, who raised $10m to advance drug discovery & treatments for rare diseases, set to speak at 8th Annual Orphan Drugs and Rare Diseases Conference

LONDON, WATERLOO, UNITED KINGDOM, August 14, 2018 /EINPresswire.com/ — Healx, a HealthTech company based in Cambridge who are also set to speak at this year’s Orphan Drugs and Rare Diseases conference in October in London, have announced a $10m (£7.6m) Series A funding round. The company's primary focuses include using AI to develop treatments for rare diseases, cutting down the time it takes to get drugs into market, finding new uses for existing drugs and their application in combination therapies.

Patients with rare diseases cannot continue to be overlooked because of costly therapies and have the same rights to treatment as any other patient. Dr David Brown, one of the company's founders, stated “The traditional drug discovery process takes 10 to 15 years at a cost of $2 billion per new drug and with a failure rate of 95% – it’s broken, it’s slow, it’s high failure, and it’s not economic for rare diseases. Healx is showing that we can massively transform the rate of discovery of new medicines, reducing timelines and costs.”*

The orphan drugs market has seen a huge growth in interest from pharmaceutical companies and biotechs, as a growing need for effective, long-term treatment for rare disease patients becomes a priority. Companies like Healx are paving the way to success by repurposing existing drugs, meaning fewer complex trials, less expenditure, and a quicker timeline.

This year's 8th annual Orphan Drugs and Rare Diseases conference, taking place 17 – 18 October in London, will be hosting Healx's Head of Business Development Michale Bouskila-Chubb, who is set to present on "Accelerating drug discovery for rare diseases using AI: The Healx Model".

Michale will be focusing on fragile X case study: the case for AI-driven drug repurposing vs conventional drug repurposing, setting up an online tool to share data: how patient groups can accelerate data access and data quality for their rare diseases, and translating repurposed drugs to pharma: how we can build viable commercial cases for the pharmaceutical industry.

At this year’s two-day conference, delegates will be able to hear from Healx and many more industry leaders, including Sobi, MHR AstraZeneca, Genetic Alliance and more.

2018 Conference Highlights:

• Discuss the pricing and reimbursement of orphan drugs
• Understand the challenges of patient recruitment and patient-centric research
• Hear the MHRA’s perspective on benefit-risk assessment in rare diseases
• Explore the clinical development of orphan drugs for rare diseases
• Gain insight into potential synergies between regulators, non-profits and pharmaceutical companies

The conference’s last early bird saving of £200 expires on August 31st and delegates are urged to book soon to join an unrivalled gathering of international expert speakers and industry professionals for 5+ hours of pure networking. Visit the website to download the full speaker interviews, see the agenda and keep up to date with the latest developments at http://www.orphandrugs.co.uk/einpr

*uktech.news

—- END —
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Maria Mandic
SMi Group
email us here
+44 (0) 207 827 6000


Source: EIN Presswire

SMi’s Exclusive Interview with Mark Albrecht, Project Officer, HHS/ASPR/BARDA

Interview: Mark Albrecht

NEW JERSEY , ISELIN, USA, August 13, 2018 /EINPresswire.com/ — SMi Reports: An exclusive interview with Biomedical Advanced Research and Development Authority (BARDA) acting Chief Mark Albrecht has been released in the run-up to the 3rd annual Superbugs & Superdrugs USA Conference taking place in Iselin, New Jersey on November 12 – 13, 2018.

Mark provided us with some insightful content about his role in the field, his view on challenges within the field and his vision on the future of the development of novel anti-infectives. His presentation will focus on ‘Supporting Antibacterial Research and Development’, how BARDA partners with industry to stimulate innovation in AMR R&D and how CARB-X is refilling the preclinical AMR product pipeline.

He works closely with product sponsors to advance the development of their antibacterial candidates, towards consideration for regulatory approval for both public health and biodefense indications, coordinating efforts to advance the development of bio-defence medical countermeasures and ensure that Government agency portfolios are properly aligned.

By attending our 3rd annual Superbugs & Superdrugs USA event, not only would you benefit from the knowledge delivered through a range of thought-provoking presentations, by experts at the forefront of the field; but you would also receive the opportunity to interact with and exchange ideas with decision makers from all of the different facets of the industry – from research to commercial providers and regulatory bodies.

–SNAPSHOT OF INTERVIEW–

Q. What do you see as the greatest hurdle to developing novel and effective anti-infectives?
A. There are a variety of challenges affecting the antibacterial development industry including optimal pipeline composition to withstand attrition and the development of resistance, and clarity on the development/regulatory path for a single pathogen anti-infective; however, there has been far greater discussion regarding the lower commercial returns antibiotics generate compared to other therapeutic areas such as cancer or heart disease. Given that antibiotic development is financially challenging with an uncertain return on investment (ROI) it is clear that both push mechanisms (CARB-X, GARD-P, NIAID, Wellcome Trust, BARDA, etc.) and pull incentives are necessary. In particular, pull incentives will ensure companies have a predictable ROI for developing these drugs that society requires, but undervalues. Dozens of publications have described a variety of incentive structures, any of which would involve tradeoffs for all parties, including sponsors, non-profit organizations, and payers, therefore, there is work to be done to establish a consensus recommendation for policymakers.

Q. What do you hope to gain from this meeting?
A. I am looking forward to the opportunity to meet all the attendees and speak with them about their products, challenges and the opportunities that CARB-X and BARDA offer.
At this year’s two-day conference, delegates will be able to hear from HHS/ASPR/BARDA and many more industry leaders, including Scynexis, Janssen, Octagon Therapeutics, Astellas and more.

– Download the full interview online –

2018 Conference Highlights:
* Gain Insight into Diagnostic Technologies being used in the field and the futuristic developments
* Learn about pathogen focused drug development
* Hear from the main regulatory bodies to advise on guidelines surrounding funding and development
* Explore new companies on developing novel approaches to circumvent antibacterial resistance
* Discover new approaches of anti-fungal development
* Case-study examples of rapid diagnostic methods currently being used in the field
* Network with key industry leaders and benefit from though provoking discussions

The conference’s last early bird saving of US$100 expires on September 28th and delegates are urged to book soon to join an unrivalled gathering of international expert speakers and industry professionals for 5+ hours of pure networking. Visit the website to download the full speaker interviews, see the agenda and keep up to date with the latest developments at www.superbugs-usa.com/pr7

SMi presents the 3rd annual industry leading conference:
Superbugs & Superdrugs USA
Date: 12th – 13th November 2018
Location: Renaissance Woodbridge Hotel, Iselin, New Jersey
Website: www.superbugs-usa.com/pr7

Contact Information:
For sponsorship bookings, contact Alia Malick Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
Book your place online at www.superbugs-usa.com/pr7

Follow us on: Twitter – @SMIpharm & #smibugs | LinkedIn – @SMi Pharma

—- ENDS —-

About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+44 (0) 207 827 6088
email us here


Source: EIN Presswire

Engineering a Perfect Baby Revealed in a Book

“Under the Spreading Chestnut Tree”

Engineering a Perfect Baby Revealed in a Book

NEW ROCHELLE, NY, UNITED STATES, August 10, 2018 /EINPresswire.com/ — Set in the cyberpunk year 2102, "Under the Spreading Chestnut Tree", penned by New York writer Hilary Smith, puts together individuals and situations that will challenge and disturb your preconceptions about the possible evolution of motherhood.

This novel opens in the world of advanced medicine and genetically engineered humans, when babies are conceived from eggs and sperm that are prescreened for all known genetic disorders. Heritable diseases and infectious diseases are wiped out, and scientists can re-engineer every body part and organ.

Hilary Smith imagines the trajectory of technology, with a fast-paced story line filled with scientific break-throughs, natural disasters and government conspiracies. She takes her readers to a riveting not-so-distant future as her realistic, imperfect protagonists tackle through their own journeys.

A medical expert who completed her pediatric residency training at Bellevue / NYU, Hilary Smith has brought her widespread knowledge to one of the world’s thorniest issues that is certain to be controversial.

It is no longer a question of whether "designer babies" can be created but it is a question of whether we should; a tug-of-war in man's moral compass. This novel will bring about in-depth discussion and contemplation, coupled with an engrossing story and relatable, beloved characters.

About the Author:
Hilary Smith grew up as an only child in White Plains, NY and then studied science and Spanish at SUNY Albany. She went on to NYU medical school and completed her pediatric residency training at Bellevue / NYU. Currently, She's working at a small pediatric practice in downtown New Rochelle. Hilary and her husband have two wonderful, loving, active boys. In her spare moments she like to work out, play piano and clarinet, listen to opera, and of course, write.

Product details
Paperback: 312 pages
Publisher: Authorcentrix, Inc. (May 10, 2018)
Language: English
ISBN-10: 1641332751
ISBN-13: 978-1641332750
Product Dimensions: 6 x 0.7 x 9 inches

Book Availability:
Amazon –http://amzn.to/2m8ExGt
Barnes & Noble – http://bit.ly/2NAwP4u
Book Depository – http://bit.ly/2m3vqqA

Hilary Smith
.
888 504 0951
email us here


Source: EIN Presswire

AUTEC POWER SYSTEMS IS COMMITTED TO CONFLICT-FREE MINERALS

Conflict Free Minerals Only

Ensuring Ethical Practices and Products Through Conflict-Free Minerals

WESTLAKE VILLAGE, CA, USA, August 10, 2018 /EINPresswire.com/ — Autec Power Systems has been committed to ethical business practices since our inception. This has never been more important than with the rise of conflict minerals used in electronic components throughout the technology industry in the last decade. These minerals include tin (cassiterite ore), tungsten (wolframite ore), tantalum (coltan ore), and gold. It's important to note that these minerals are used extensively in not only power supplies and power solutions, but throughout society in things like airplanes, cell phones, jewelry and medical equipment. Militant groups in the Democratic Republic of the Congo have used the theft, sale and profits from these minerals to wage war and sustain a more than decade long conflict. Pressure from organizations seeking ethical alternatives has caused the United States government to pass a measure requiring the disclosure of supply chains from consumer electronics companies. Thanks in large part to these efforts and the overall addressing of this major international issue by the public, the number of militant controlled mines and refiners have been greatly reduced allowing for more conflict-free mineral sources.

It is Autec Power Systems policy to not intentionally or knowingly purchase products, components, or materials that contain conflict minerals. We strive to avoid contributing to conflicts through our sourcing practices. Autec Power Systems is taking steps to ensure that the use of key component materials meet the aforementioned Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. We request our suppliers be DRC conflict-free and source from smelters validated as compliant to a Conflict-Free Smelter protocol using the CFS Compliant Smelter List. We also require suppliers to provide a completed Conflict Minerals Reporting Template to provide reasonable assurance that the specified minerals are not being sourced from “Conflict Regions.” We ask our suppliers to work with us in our efforts to ensure we procure non-conflict minerals. We encourage our suppliers to responsibly source non-conflict minerals and derivative metals from the DRC and neighboring countries in order to prevent an embargo and associated worsening of economic conditions and human suffering.

To read more regarding our commitment to ethical business practices and the use of conflict-free minerals in
our power solutions, the full conflict mineral statement can be found at www.autec.com

Gregg Angell
Autec Power Systems
8183387788
email us here


Source: EIN Presswire

Plasma Protein Therapeutics Market – What are the latest revenue forecasts? | Report 2023

Plasma Protein Therapeutics

Plasma Protein Therapeutics

Plasma Protein Therapeutics Market By Product Type, By Application, And By Region – Global Industry Analysis, Size, Share Trends, And Forecasts (2018-2023)

Severe blood conditions offers a vast market potential for their growth in the forecast period”

— Lead Analyst @ Market Data Forecast

HYDERABAD, TELANGANA, INDIA, August 10, 2018 /EINPresswire.com/ — Plasma is the fluid content of the blood that is responsible for preventing many serious ailments attacking the human body. The proteins in the blood plasma comprise minerals, vitamins, lipids, and hormones, which are essential for clotting and fighting alien organisms invading the human immune system. They are also helpful in the control of blood pressure, whole blood viscosity and other interior activities. The liver plays a pivotal role in synthesizing almost all these proteins. Albumins, Globulins, and Fibrinogen are the most prominent plasma proteins in the human blood.

The Global Plasma Protein Therapeutics Market Size is estimated to be at USD 23935.47 Million in 2018 and is poised to reach USD 36777.04 Million by 2023 with a CAGR of 8.97%.

Plasma Protein Therapeutics refers to the drugs or medicines that can be manufactured with the aid of proteins derived from blood plasma. The therapeutics can be used to treat many chronic illnesses like neurological and blood disorders, genetic diseases, hepatitis, Rabies and many others by enhancing the immune system and the disease resistance capacity of the victims.

Request for sample: https://marketdataforecast.com/market-reports/global-plasma-protein-therapeutics-market-235/request-sample

The increasing need for the use of Immunoglobulin along with the introduction of the new variety of plasma-derived drugs acts as a primary catalyst for the growing demand for plasma protein therapeutics. The other factors include growing geriatric population, the prevalence of chronic diseases, growing investments in the research and development of medical sciences, hassle-free technological processes for the extraction of plasma from blood, and raising awareness among people about the significance of the blood donation.

On the other hand, the implementation of strict government policies, lack of proper reimbursement procedures, issues involved in the manufacturing of biological drugs, underdeveloped medical and healthcare facilities in remote areas of developing nations, unhygienic storage facilities and other aspects may impede the expansion of the plasma protein therapeutics market internationally.

Get full report @ https://marketdataforecast.com/market-reports/global-plasma-protein-therapeutics-market-235/

The full report provides a deep insight into the global market of plasma protein medicines including its share, size, trends, analysis, and forecast along with the accurate information of its regional presence and competitive landscape. The global plasma protein therapeutics market is divided on the basis of product type, application, and geographical regions.

Based on the product type, Immunoglobulin accounts for more than half of the total market share due to the rise of chronic and life-threatening diseases. The increasing use of immunoglobulin in the fields of hematology, neurology, rheumatology, and other genetic disorders has fueled the market expansion. Also, the need for coagulation factors in severe blood conditions like liver infections and Von Willebrand's disease offers a vast market potential for their growth in the forecast period.

Based on the application, Primary Immunodeficiency Disorders are the leading market contributors and expected to continue the same trend in the forecast period. The main reason for this segment growth is the extensive use of immunoglobulin and human albumins in many medical practices. Apart from this, the secondary Immunodeficiency disorders like malnutrition, diabetes, HIV, myeloma, and others can also aid in the promotion of the global plasma protein therapeutics market.

Based on the geographical distribution, the international market is divided into the regions of North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America with the hefty investments in research and development of the medical field, growing elderly populace, increasing blood donations and the invention of new products grabs almost 40% of global plasma proteins market followed by Europe. Various applications of this therapeutics in the field of neurology, ophthalmology, nephrology, dermatology, and others offer a high demand for the plasma protein drugs in Europe.

Customized report: https://marketdataforecast.com/market-reports/global-plasma-protein-therapeutics-market-235/customize-report

There only a few famous market contributors for the worldwide plasma proteins other than the new entrants in respective regions. CSL Behring is considered to be the global leader in terms of revenue followed by Octapharma, Grifols, and Baxalta. Other important market players include Kedrion, Telecris, Baxter International, Shire Plc, Chengdu Inst. and few non-profit organizations like the Red Cross. Though CSL Behring leads the world market for plasma protein medicines, Grifols has the dominating share of the alpha-1 antitrypsin and IV immunoglobulin markets.

The scope of the report:
• Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the untapped regions.
• The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
• Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
• Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economic, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
• Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
• A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions

Download Free sample @ Middle East And Africa Angina Pectoris Drugs Market, Middle East And Africa Schizophrenia Drugs Agents Market

Contact info:
Abhishek Shukla
Team Lead (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com

Sai Kutumbarao
Market Data Forecast
7680952236
email us here


Source: EIN Presswire

Global Interventional radiology Market Research and Forecast 2018-2023

Global Interventional radiology Market Research by OMR

Orion market Research OMR Analyst

Global Interventional radiology (IR) Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

Emergence of cloud-based medical imaging will drive the growth of interventional radiology market.”

— OMR Analyst

INDORE, INDIA, August 9, 2018 /EINPresswire.com/ — According to the OMR analysis, the global interventional radiology market is growing at a CAGR of 6.8% during forecast period 2018-2023. The global interventional radiology market has witnessed a significant growth due to technological advancement, cohesive government and reimbursement policies. The global interventional radiology market is segmented on the basis of diagnostic modalities, by application, by procedure and geography. The report provides detailed and insightful chapters on market overview, key findings, strategic recommendations, market determinants, market insights, key company analysis, company profiling, market segmentation, geographical analysis, analyst insights.

Full report of global interventional radiology market is available at: https://www.omrglobal.com/industry-reports/interventional-radiology-market/

“Emergence of cloud-based medical imaging is seen as an opportunity in the global interventional radiology market. Cloud-based medical imaging informatics is one of the cost-effective and flexible solutions available in the industry. Medical imaging systems using cloud computing paradigm are in trend owing to its economies of scale, pay per use model, maintenance cost reduction, ease of information sharing and so on. Decreasing human error makes cloud-based imaging system a key solution for health IT infrastructure and diagnosis. Implementation of a cloud-based solution not only lowers the cost across an entire healthcare organization but also reduces the budget for other necessities. The future of medical imaging informatics is firmly tied to the cloud. As population globally has been forwarding towards the innovator stage, healthcare industry also evolved around greater data usability and interoperability in healthcare.”
The market on the basis of geography has been divided among four major regions – North America, APAC, Europe, and Rest of the world. North America is the leading market. The market is expected to grow at a stable CAGR. North American market is driven by high healthcare spending, well-developed healthcare infrastructure, presence of most of the major companies such as GE healthcare, Hologic, Philips, reimbursement policies, technological advancement and adoption of hybrid operating rooms and minimally invasive surgeries. Asia Pacific market is expected to have the highest CAGR amongst all regions during the forecast period of 2018-2023.

The report covers:
Comprehensive research methodology of global interventional radiology market
In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global interventional radiology market
Insights about market determinants which are stimulating the global interventional radiology market
Detailed and extensive market segments with regional distribution of researched revenues
Extensive profiles and recent developments of market players

For related reports please visit https://www.omrglobal.com/reports-category/medical-devices/

About Orion Market Research
OMR is a market research company known for its qualitative and quantitative research reports. The company aims to provide business insights for decision making to the global clients. OMR provides syndicated and customized research reports, company profiling, consulting and other research-based services to global clients. The “Orion” in the name signifies rising up in the sky, the company is committed to provide valuable insights that will help its clients to rise and shine. OMR provide customer-centric reports which facilitate the subscribers to know their touch points which can be capitalized for their revenue growth and to gain a competitive edge.

Anurag Tiwari
Orion Market Research Pvt. Ltd.
+919179828694
email us here

Global Interventional radiology Market Research Report by Orion Market Research


Source: EIN Presswire

Donald Zandier of Enlight Treatment to be Featured on CUTV News Radio

BETHEL PARK, PENNSYLVANIA, UNITED STATES, August 9, 2018 /EINPresswire.com/ — We have many effective ways of healing our physical body, but until now we’ve had no application to broadly and deeply heal our emotional body.

Donald Zandier is a Psychologist and the creator of Enlight treatment, a revolutionary modality designed to heal a lifetime of harmful emotional experiences and free individuals of the bad habits they have developed to cope with these experiences.

According to Zandier, our experiences are stored in our subconscious like information on a computer. Sometimes the emotions we associate with our experiences are processed and we feel better, but more often than not, we don’t fully process these emotions, and over time, these unprocessed negative emotions accumulate “like barnacles on the bottom of a boat.”

Based on the results Zandier has observed, he believes that the Enlight method painlessly accesses both the conscious and subconscious experiences that still possess a negative emotional charge. Then, Enlight removes the active emotional discomfort associated with each experience.

Enlight treats the causes of emotional distress. Sadness and anxiety appear to improve after healing the subject’s history of harmful emotional experiences. The key emotional experiences are trauma and what Zandier calls emotional malnourishing experiences. Moreover, reduces bad habits by focusing treatment on the temporary relief associated with all of our bad habits.

“Bad habits develop as a means of coping with our pain,” says Zandier. “However, these habits never heal the source of our discomfort and eventually cause additional problems.”

Zandier developed the Enlight treatment after experiencing frustration as a psychologist.

“I’ve always had a natural compassion for people and a desire to relieve their suffering,” says Zandier. “Early in my career, I didn’t feel I was making nearly as much of a difference as I thought I would. I was anxious for something that would work better. When I found this, I was like a kid in a candy store.”

Zandier has refined his approach for the past 25 years, and now offers an online application. He says he is most proud of how well Enlight works on the average person.

“We all have some degree of negative emotional history and bad habits which Enlight can clear,” says Zandier. “Therefore this approach can improve society’s emotional health in general.”

Enlight is not a replacement for medical treatment but a supplement that may greatly enhance treatment as usual.

CUTV News Radio will feature Donald Zandier in an interview with Doug Llewelyn on August 13th at 1pm EDT.

Listen to the show on BlogTalkRadio. If you have a question for our guest, call (347) 996-3389.

For more information, visit www.enlighttreatment.com

Lou Ceparano
CUTV News
(631) 850-3314
email us here


Source: EIN Presswire